Scientists search genes to Fine-Tune cancer drug dosing
NCT ID NCT02404584
Summary
This study aimed to understand why the cancer drug sunitinib works differently in different people. Researchers followed 43 patients with metastatic kidney cancer who were starting the drug. They measured drug levels in the blood, tracked side effects and tumor response, and looked for links to patients' genetic makeup to learn how to potentially use the drug more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Montpellier - Hôpital Saint-Eloi
Montpellier, 34295, France
-
CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
-
Institut de Cancérologie du Gard (ICG)
Nîmes, 30029, France
Conditions
Explore the condition pages connected to this study.